William Blair Comments on Agenus’ Q1 Earnings (NASDAQ:AGEN)

Agenus Inc. (NASDAQ:AGEN) – Equities researchers at William Blair upped their Q1 2025 earnings per share (EPS) estimates for shares of Agenus in a research report issued to clients and investors on Tuesday, March 11th. William Blair analyst M. Phipps now forecasts that the biotechnology company will post earnings of ($1.17) per share for the quarter, up from their previous forecast of ($1.31). The consensus estimate for Agenus’ current full-year earnings is ($12.55) per share. William Blair also issued estimates for Agenus’ Q2 2025 earnings at ($0.90) EPS, Q3 2025 earnings at ($0.75) EPS, Q4 2025 earnings at ($0.67) EPS, FY2025 earnings at ($3.48) EPS, FY2026 earnings at ($2.58) EPS and FY2027 earnings at ($2.51) EPS.

Agenus (NASDAQ:AGEN) last announced its quarterly earnings data on Tuesday, March 11th. The biotechnology company reported ($2.04) earnings per share for the quarter, beating the consensus estimate of ($2.36) by $0.32. The company had revenue of $26.84 million during the quarter, compared to analyst estimates of $30.09 million.

Other equities analysts have also recently issued research reports about the company. HC Wainwright reissued a “neutral” rating on shares of Agenus in a report on Wednesday. Robert W. Baird lowered their price target on Agenus from $6.00 to $3.00 and set a “neutral” rating for the company in a report on Wednesday. One analyst has rated the stock with a sell rating, five have given a hold rating and one has assigned a buy rating to the company. According to data from MarketBeat.com, the stock has a consensus rating of “Hold” and a consensus price target of $8.75.

Agenus Stock Performance

Agenus stock opened at $1.86 on Friday. Agenus has a 52 week low of $1.65 and a 52 week high of $19.69. The stock has a market capitalization of $43.63 million, a P/E ratio of -0.17 and a beta of 1.23. The stock has a fifty day moving average of $3.17 and a 200-day moving average of $3.80.

Institutional Investors Weigh In On Agenus

A number of hedge funds and other institutional investors have recently bought and sold shares of the company. Deutsche Bank AG grew its position in Agenus by 538.4% during the 4th quarter. Deutsche Bank AG now owns 61,144 shares of the biotechnology company’s stock worth $168,000 after acquiring an additional 51,566 shares during the last quarter. Corton Capital Inc. bought a new stake in shares of Agenus in the 4th quarter valued at about $36,000. Bank of America Corp DE grew its position in shares of Agenus by 34.0% in the 4th quarter. Bank of America Corp DE now owns 107,123 shares of the biotechnology company’s stock valued at $294,000 after buying an additional 27,157 shares during the last quarter. Jane Street Group LLC grew its position in shares of Agenus by 97.6% in the 4th quarter. Jane Street Group LLC now owns 105,705 shares of the biotechnology company’s stock valued at $290,000 after buying an additional 52,215 shares during the last quarter. Finally, B. Riley Financial Inc. bought a new stake in shares of Agenus in the 4th quarter valued at about $2,074,000. Institutional investors own 61.46% of the company’s stock.

Agenus Company Profile

Agenus Inc, a clinical-stage biotechnology company, discovers and develops immuno-oncology products in the United States and internationally. The company offers Retrocyte Display, an antibody expression platform for the identification of fully human and humanized monoclonal antibodies; and display technologies.